MeiraGTx Holdings plc (MGTX)

NASDAQ: MGTX · IEX Real-Time Price · USD
8.12
-0.23 (-2.75%)
Feb 3, 2023, 4:00 PM EST - Market closed
-2.75%
Market Cap 393.63M
Revenue (ttm) n/a
Net Income (ttm) -112.21M
Shares Out 48.48M
EPS (ttm) -2.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 107,495
Open 8.23
Previous Close 8.35
Day's Range 8.04 - 8.39
52-Week Range 5.70 - 15.87
Beta 1.37
Analysts Buy
Price Target 29.73 (+266.13%)
Earnings Date Mar 9, 2023

About MGTX

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE6... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 361
Stock Exchange NASDAQ
Ticker Symbol MGTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MGTX stock is "Buy." The 12-month stock price forecast is $29.73, which is an increase of 266.13% from the latest price.

Price Target
$29.73
(266.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference cal...

2 months ago - GlobeNewsWire

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...

2 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...

3 months ago - Zacks Investment Research

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx...

4 months ago - GlobeNewsWire

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which...

4 months ago - GlobeNewsWire

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

-- Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization

5 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

6 months ago - GlobeNewsWire

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

- Credit facility is collateralized by MeiraGTx's wholly-owned manufacturing facilities in London, UK and Shannon, Ireland

6 months ago - GlobeNewsWire

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated

7 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients -  Phase 1 AQUAx Study of AAV-hAQP1 for Radi...

9 months ago - GlobeNewsWire

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

LONDON and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that additional clinical data f...

9 months ago - GlobeNewsWire

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D....

10 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?

MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...

11 months ago - Zacks Investment Research

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto...

11 months ago - Zacks Investment Research

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

- Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing Patients - Received $30 Million Cash Milestone P...

11 months ago - GlobeNewsWire

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

-MeiraGTx Receives $30 Million Cash Milestone Payment

1 year ago - GlobeNewsWire

A Biotech Unveils Its New Gene Control Technology

MeiraGTx says it has a triggering drug that can be used to turn implanted genes on and off in people. The technology could lessen the cost of treatment for many illnesses.

1 year ago - Barrons

MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation

LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and c...

1 year ago - GlobeNewsWire

MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom

MeiraGTx Holdings plc (NASDAQ: MGTX) has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX). Xerostomia, or Dry mouth, happen...

1 year ago - Benzinga

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

LONDON and NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive preliminary data fro...

1 year ago - GlobeNewsWire

MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation

LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference cal...

1 year ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st...

1 year ago - Zacks Investment Research

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results

LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the thi...

1 year ago - GlobeNewsWire